静脉注射左西孟旦治疗晚期严重心力衰竭患者的疗效分析

doi:10.3969/j.issn.1002-1949.2018.08.012

Chinese Journal of Critical Care Medicine

2018, Vol. 38

Issue (8): 706-710 DOI: 10.3969/j.issn.1002-1949.2018.08.012

Efficacy of intravenous injection of levosimendan in the treatment of advanced patients with severe heart failure

Yang Fei, Wang Shao-hua, Zhao Li-na, Wang Yun-ying, Chen Zhuang

Intensive Care Unit, Chifeng Municipal Hospital, Chifeng College of Clinical Medicine, Inner Mongolia Medical University, Chifeng 024000, China

Abstract
Figure/Table
References (15)
Related Citation (0)

Download: PDF (493 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the effect of levosimendan on the treatment of advanced patients with severe heart failure. Methods Using a retrospective study method, 60 patients with advanced severe heart failure in ICU of Chifeng Municipal Hospital from September 2015 to October 2017 were randomly divided into the control group (group C, n=30) and the test group (group T, n=30). On the basis of basic treatment, the two groups were treated with barphenbutylamine 4 μg/（kg·min） continuous pumping for 24 h (group C) and levsimendan 0.1 μg/kg·min continuous pumping for 24 h (group T) respectively. At three points of before treatment (T0), 24 h after treatment (T1), 72 h after treatment (T2), the biochemical indexes of cardiac function of NT-proBNP, CK-MB and GAP, hemodynamic index of CVP and HR, the related indexes of left ventricular function of LVESV, LVEDV, LVESD, LVEDD, LVEF and LVSF, the related indexes of right ventricular function of RVEF, RVLD, RVDD and PASP, liver function indexes of SCr, ALT and AST, were recorded. Results There was no significant difference in gender, APACHEⅡ score, age, BMI and NYHA grade between the two groups (P>0.05). Compared with T0 time and C group, NT-proBNP, CK-MB, GAP, CVP and HR decreased significantly (P<0.05); LVEF and LVSF increased and LVESV, EPSS, LVESD decreased significantly (P<0.05); RVEF increased and RVLD, RVDD, PASP decreased significantly (P<0.05); SCr, ALT and AST decreased significantly (P<0.05) in group T at T1 and T2. Conclusion The cardiac function of patients with advanced severe heart failure can be significantly improved by routine therapy adding levosimendan for 24 hours, and the therapeutic effect is significant.

Key words： Levosimendan Serious heart failure NT-proBNP CK-MB

Corresponding Authors: Chen Zhuang, E-mail: cfsicu@163.com

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Yang Fei
	Wang Shao-hua
	Zhao Li-na
	Wang Yun-ying
	Chen Zhuang

Cite this article:

Yang Fei,Wang Shao-hua,Zhao Li-na, et al. Efficacy of intravenous injection of levosimendan in the treatment of advanced patients with severe heart failure[J]. Chinese Journal of Critical Care Medicine, 2018, 38(8): 706-710.

URL:

http://www.cnemergency.org.cn/EN/10.3969/j.issn.1002-1949.2018.08.012 OR http://www.cnemergency.org.cn/EN/Y2018/V38/I8/706

［1］ Campodonico J, Mapelli M, Spadafora E, et al. Surfactant proteins changes after acute hemodynamic improvement in patients with advanced chronic heart failure treated with Levosimendan［J］. Respir Physiol Neurobiol, 2018, 252-253:47-51. ［2］Shang G, Yang X, Song D, et al. Effects of Levosimendan on Patients with Heart Failure Complicating Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials［J］. Am J Cardiovasc Drugs, 2017, 17(6):453-463. ［3］Nieminen MS, Dickstein K, Fonseca C, et al. The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations［J］. Int J Cardiol, 2015, 191:256-264. ［4］Jiang R, Zhao QH, Wu WH, et al. Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension［J］. Clin Respir J, 2018, 12(4):1518-1525. ［5］杨书凤, 周湘忠, 桑红斌. 左西孟旦对充血性心力衰竭患者LVEF及血浆NT-proBNP的影响［J］. 继续医学教育, 2018, 32(2):153-155.［6］王建军, 董海山, 温丽荣. 入院时心力衰竭对感染性休克患者预后的影响［J］. 中国急救医学, 2018, 38(1):26-30. ［7］Fruhwald S, Pollesello P, Fruhwald F, et al. Advanced heart failure: an appraisal of the potential oflevosimendan in this end-stage scenario and some related ethical considerations［J］.Expert Rev Cardiovasc Ther, 2016, 14(12):1335-1347. ［8］Horvath B, Bers DM. The late sodium current in heart failure: pathophysiology and clinical relevance［J］. Esc Heart Failure, 2015, 1(1):26-40. ［9］杨晓慧, 王力.左西孟旦对急性失代偿性心力衰竭患者血流动力学的影响［J］. 中国急救医学, 2015, 35(z2):59-60. ［10］Oner E, Erturk M, Birant A, et al. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure［J］. Cardiol J, 2015, 22(1):87-93. ［11］Farmakis D, Alvarez J, Gal TB, et al. Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper［J］. Int J Cardiol, 2016, 222:303-312. ［12］Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis［J］. Int J Cardiol, 2016, 202:138-143. ［13］Nieminen MS, Buerke M, Cohen-Solál A, et al. The role of levosimendan in acuteheart failure complicating acute coronary syndrome: A review and expert consensus opinion［J］. Int J Cardiol, 2016, 218:150-157. ［14］Fruhwald S, Pollesello P, Fruhwald F. Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations［J］. Expert Rev Cardiovasc Ther, 2016, 14(12):1335-1347. ［15］Kivikko M, Sundberg S, Karlsson MO, et al. Acetylation status does not affect levosimendan′s hemodynamic effects in heart failure patients［J］. Scand Cardiovasc J, 2011, 4(5):86-90.